StreetAlpha.app
Home › Stocks › GHRS

GH Research PLC (GHRS)

Healthcare
$18.27
▼ −2.56%
LAST CLOSE · NOV 17

GH Research develops mebufotenin-based treatments for depression and other psychiatric and neurological disorders. It last closed at $18.27 on Nov 17, down 2.56% on the day.

AI Auto Pilots
Is GHRS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$48.3M
Free cash flow
−$43.7M
Balance sheet
Cash & equivalents
$246.3M
At Dec 31
Debt
$0
At Dec 31
Shareholder equity
$279.7M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$9.2M−$9.2MFY2021FY2022: −$22.5M−$22.5MFY2022FY2023: −$35.6M−$35.6MFY2023FY2024: −$39.0M−$39.0MFY2024FY2025: −$48.3M−$48.3MFY2025

From GHRS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 5). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated GHRS in the past 90 days, not enough for a consensus
Average 12-month target
$55.00
▲ 201.0% upside

Based on 1 analyst who set a price target on GHRS in the past 90 days. The average target is $55.00, with a high of $55.00 and a low of $55.00, compared with the last close of $18.27.

Low $55.00Avg $55.00High $55.00
Blue marker: last close $18.27
Highest target$55.00
Average target$55.00
Lowest target$55.00
Latest rating changes
HC Wainwright & Co.Target lowered
Nov 17Buy$65 → $55
GuggenheimMaintained
Aug 7Buy$40
Cantor FitzgeraldMaintained
Aug 7Buy$40
NeedhamMaintained
Aug 6Buy$39
Wells FargoInitiated
Jul 27Buy$44
DateFirmActionRatingPrice target
Nov 17HC Wainwright & Co.Target loweredBuy$65 → $55
Aug 7GuggenheimMaintainedBuy$40
Aug 7Cantor FitzgeraldMaintainedBuy$40
Aug 6NeedhamMaintainedBuy$39
Jul 27Wells FargoInitiatedBuy$44
Loading…

Technical Analysis

GHRS · as of the Nov 17 close · updated after every close
Downtrend

The stock is 6% below its 20 day and 20% below its 50 day average. It is 19% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the swing low (Nov 6) at $18.16, and the nearest resistance the Pivot R1 at $18.63.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 6.9%/day
Key levels
$31.4452 week high+72.1%
$25.04100 day average+37.1%
$21.9250 day average+20.0%
$21.72200 day average+18.9%
$19.81Swing high (Oct 21)+8.4%
$19.4120 day average+6.2%
$18.63Pivot R1+2.0%
$18.27Last close
$18.16Swing low (Nov 6)−0.6%
$18.11Pivot−0.9%
$17.74Pivot S1−2.9%
$12.0452 week low−34.1%
Indicators
RSI (14)38.52Weak, oversold below 30Neutral
MACD-0.79Above its signal lineBullish
Stochastic20.5Middle of its rangeNeutral
ADX (14)18.5No clear trend
Williams %R-84.8Oversold below −80, overbought above −20Oversold
CCI (20)-110.4Oversold below −100, overbought above 100Oversold
Rate of change−9.9%Change over 10 sessionsBearish
ATR (14)$1.27Typical daily range, 6.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for GHRS

What happened before

See how GHRS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow GHRS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How GHRS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in GHRS in the last 90 days.

Loading…

See today’s whale options flow across the market →

GHRS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲47 buying vs 23 selling
  • ▼Shares held by funds -1.3%
  • ▲Funds holding +17
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding8063+27.0%
In funds' top 10330.0%
Held by funds–––
New / increased22 / 2517 / 18+34.3%
Reduced / sold out18 / 516 / 9−8.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GHRS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GHRS is in one of them and how their past GHRS trades turned out.

GHRS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GHRS in an article yet. Here's the latest on the wider market.

About GH Research

GH Research is a biopharmaceutical company based in Dublin, Ireland, that is developing treatments for psychiatric and neurological disorders. Its product candidates are based on mebufotenin, studied as an inhaled treatment called GH001 and as an intravenous treatment called GH002. The company's initial focus is treatment resistant depression, a form of major depressive disorder in which patients have not responded adequately to standard therapies. It has not yet received approval to sell any product, and its intended customers are patients with depression and the healthcare providers who treat them.

Headquarters
Dublin 2, Ireland